everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12345678910111213...132133»
  • ||||||||||  everolimus / Generic mfg., fulvestrant / Generic mfg.
    Journal, Circulating tumor DNA:  Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis. (Pubmed Central) -  Apr 15, 2024   
    P=N/A
    ctDNA detection at baseline and PIK3CA mutation had an adverse prognostic impact on PFS and OS in multivariate analysis. This prospective cohort study documents the efficacy of fulvestrant and everolimus in CDK4/6i-pretreated ER?+?/HER2- mBC and highlights the clinical validity of early ctDNA changes as pharmacodynamic biomarker.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. (Pubmed Central) -  Apr 13, 2024   
    Based on our experience, everolimus provides a reduction in the relative risk of hepatocellular carcinoma recurrence, especially for advanced-stage patients and those with earlier drug administration, higher drug exposure, and longer time on treatment. These data advocate for early everolimus introduction after liver transplantation to reduce the attrition rate consequent to chronic immunosuppression.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial completion date, Trial initiation date, Trial primary completion date:  Study of Ribociclib and Everolimus in HGG and DIPG (clinicaltrials.gov) -  Apr 12, 2024   
    P2,  N=100, Not yet recruiting, 
    These data advocate for early everolimus introduction after liver transplantation to reduce the attrition rate consequent to chronic immunosuppression. Trial completion date: Jan 2034 --> May 2034 | Initiation date: Jan 2024 --> May 2024 | Trial primary completion date: Jan 2028 --> May 2028
  • ||||||||||  Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Review, Journal, Adverse events:  Higher risk of hepatotoxicity associated with cabozantinib in cancer patients. (Pubmed Central) -  Apr 8, 2024   
    Collectively, these results suggest DBPR728 has the potential to treat cancers overexpressing c-MYC- and/or N-MYC. Compared with other solid tumor drugs, such as everolimus, sorafenib, sunitinib, paclitaxel, mitoxantrone-prednisone et al., cabozantinib has a higher risk of hepatotoxicity.
  • ||||||||||  Gilotrif (afatinib) / Boehringer Ingelheim
    Journal:  Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex? (Pubmed Central) -  Apr 6, 2024   
    The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer appears primarily driven by molecular features associated with the activation of the PIK3CA/AKT/mTOR pathway. Our study demonstrates that EGFR suppression might be an effective alternative treatment option for SEGAs and tubers, as well as other mTOR-associated malformations of cortical development, including FCD2B.
  • ||||||||||  Piqray (alpelisib) / Novartis
    Review, Journal:  The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances. (Pubmed Central) -  Apr 6, 2024   
    Despite favorable efficacies, our analysis shows that the majority of trials are utilizing PI3K pathway inhibitors in combination with hormone therapy and chemotherapy; implying monotherapy cannot yield huge clinical benefits, at least partly, due to the activation of compensatory mechanisms. To emphasize the beneficial effects of these inhibitors in combined-modal strategies, we also reviewed recent studies which investigated the conjugation of nanocarriers with PI3K inhibitors to reduce harmful toxicities, increase the local concentration, and improve their efficacies in the context of BC therapy.
  • ||||||||||  Xolair (omalizumab) / Roche, Novartis
    Efficacy and safety of Omalizumab in a Patient, previously undergoing liver transplantation, with facial angioedema, unresponsive to corticosteroids and antihistamines (E-TPS Display Only Digital section) -  Apr 5, 2024 - Abstract #EAACI2024EAACI_432;    
    The Patient came to our attention in January 2023, on therapy with Tacrolimus 2mg/day, Modified-release prednisone 5mg/day, Cetirizine 10mg/day, Entecavir 0.5mg/day, ASA 100mg/day, ursodeoxycholic acid 600mg/day, ImmunoHBS 1000UI/ wk, Rabeprazole 20mg/day, Amlodipine 5mg/day, Triazolam 2.5mg/day... The use of Omalizumab in a liver transplant patient treated with Tacrolimus and Entecavir suffering from facial angioedema with elevated IgE proved to be safe and effective at 12 months of follow-up in producing regression of symptoms.
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    Journal:  Liver transplantation for hepatocellular carcinoma in India: Are we ready for 2040? (Pubmed Central) -  Apr 5, 2024   
    To make predictions for 2040, we must prepare to arm ourselves with less stringent selection criteria to widen the pool of patients who may undergo transplantation and have a chance of a better outcome. With more advanced technology and better donor outcomes, LDLT will provide a cutting edge in the fight against liver cancer over the next two decades.
  • ||||||||||  everolimus / Generic mfg.
    Everolimus mitigates the risk of hepatocellular carcinoma recurrence after liver transplantation (Poster Area) -  Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1028;    
    Based on our experience, everolimus provides a reduction of the relative risk of hepatocellular carcinoma recurrence, especially for advanced-stage patients and those with earlier drug administration, higher drug exposure, and longer time on treatment. These data advocate for early everolimus introduction after liver transplantation to reduce the attrition rate consequent to chronic immunosuppression.
  • ||||||||||  Zanosar (streptozocin) / Teva
    Journal:  Responses to Medical Treatment in 192 Patients with Pancreatic Neuroendocrine Neoplasms Referred to the Copenhagen Neuroendocrine Tumour Centre in 2000-2020. (Pubmed Central) -  Mar 28, 2024   
    Work is needed to implement the recommended CT screening for LAM and improve respiratory care for TSC-LAM. (1) Overall survival was, as expected, highly dependent on grade; (2) median PFS for SSA was around 2.5 years without difference between tumors with Ki-67 above or below 10%; (3) STZ/5FU as first-line treatment exhibited a superior mPFS of 20 months compared to what has historically been reported for targeted treatments; (4) PRRT in G2 pNEN achieved an mPFS similar to first-line chemotherapy; and (5) limited treatment efficacy was observed in high-grade tumors when treated with carboplatin and etoposide or temozolomide.
  • ||||||||||  everolimus / Generic mfg.
    Journal, Adverse events, Real-world evidence, Real-world:  A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system. (Pubmed Central) -  Mar 27, 2024   
    This study provided novel insights into the monitoring, surveillance, and management of adverse drug reaction associated with Everolimus. The outcome of serious adverse events and the corresponding detection signals, as well as the unexpected significant adverse events signals are worthy of attention in order to improving clinical medication safety during treatment of Everolimus.
  • ||||||||||  everolimus / Generic mfg.
    Preclinical, Journal:  Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo. (Pubmed Central) -  Mar 27, 2024   
    Furthermore, the efficacy of everolimus was reflected in reduced 13C-labeling of TCA cycle intermediates and reduced pyruvate carboxylase activity. By using in-depth analysis of drug-induced changes in glucose metabolism in combination with measurement of drug levels in tumor and plasma, effects of metabolically targeted drugs can be explained, and novel targets can be identified.
  • ||||||||||  Enrollment open:  Rapalog Pharmacology (RAP PAC) Study (clinicaltrials.gov) -  Mar 26, 2024   
    P1,  N=72, Recruiting, 
    Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jan 2024 --> Jan 2025 Not yet recruiting --> Recruiting
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    P1/2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal, Metastases:  Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. (Pubmed Central) -  Mar 24, 2024   
    P1b/2a
    Multi-omics data from the phase IIa patients (n?=?24 tumor/17 blood biopsy exomes; n?=?27 tumor transcriptomes) showed potential mechanisms of resistance (convergent evolution of HER2 activation, BRAFV600E), identified joint genomic/transcriptomic resistance features (ESR1 mutations, high estrogen receptor pathway activity, and a Luminal A/B subtype; ERBB2/BRAF mutations, high RTK/MAPK pathway activity, and a HER2-E subtype), and provided hypothesis-generating results suggesting that mTOR pathway activation correlates with response to the trial's therapy. Our results illustrate how genome and transcriptome sequencing may help better identify patients likely to respond to CDK4/6i therapies.
  • ||||||||||  Lutathera (lutetium Lu 177 dotatate) / Novartis
    New P2 trial:  LUMEN-1: 177Lu-DOTATATE for Recurrent Meningioma (clinicaltrials.gov) -  Mar 22, 2024   
    P2,  N=135, Not yet recruiting, 
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Chemical Proteomics Reveals that the Anticancer Drug Everolimus Affects the Ubiquitin-Proteasome System. (Pubmed Central) -  Mar 14, 2024   
    Moreover, the everolimus treatment resulted in both ubiquitin phosphorylation and generation of a significant amount of semitryptic peptides, illustrating the increase in the protease activity. These observations suggest that everolimus affects the UPS in a unique way, and its mechanism of action is different from that of its close chemical analogs, rapamycin and temsirolimus.
  • ||||||||||  ganitumab (AMG 479) / Takeda, ImmunityBio, Torisel (temsirolimus) / Pfizer
    Trial completion date, Trial primary completion date, Metastases:  Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma (clinicaltrials.gov) -  Mar 11, 2024   
    P1,  N=20, Not yet recruiting, 
    Therefore, it is clinically relevant to investigate further the levels of ErbB3 in patients receiving AR antagonists and evaluate the effectiveness and safety of ADT with mTOR inhibitors. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  phenytoin / Generic mfg., everolimus / Generic mfg.
    Journal:  Current views on the treatment of insulinoma (Pubmed Central) -  Mar 8, 2024   
    The rare frequency of insulinoma makes it difficult to conduct randomized controlled trials and prospective studies. That is why physicians and scientists need to maintain close contacts with each other and take into account the experience of treating each patient with such disease, which will help develop effective treatment algorithms in the future.
  • ||||||||||  everolimus / Generic mfg.
    Retrospective data, Journal:  mTor-inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy. (Pubmed Central) -  Mar 8, 2024   
    That is why physicians and scientists need to maintain close contacts with each other and take into account the experience of treating each patient with such disease, which will help develop effective treatment algorithms in the future. Initiating everolimus within the first 14?days after HTX seems to be well tolerated, enabling a low incidence of rejection, post-transplant lymphoproliferative disorders, renal failure, and reveals no evidence of cardiac allograft vasculopathy as well as good overall survival in pediatric heart transplant recipients.
  • ||||||||||  CARACTERIZACI (TUE-107; Main Foyer) -  Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1149;    
    This complication is more often observed in patients who underwent cardiac transplants, but is considered rare in other types of transplant patients. Los pacientes que presentan una progresi